LaBrosse Nicole's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Sep 11, 2025
- Accession no.
- 0001415889-25-024295
- Filed
- Sep 11, 2025
- Trade date
- Sep 10, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.51M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBrosse NicoleCIK 0001910662 | Officer (SVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Common Stock | MOption exerciseAcquired | +11,271 | $12.07 | +$136,040.97 | 43,171 | Direct | |
| Sep 10, 2025 | Common Stock | MOption exerciseAcquired | +1,135 | $12.49 | +$14,176.15 | 44,306 | Direct | |
| Sep 10, 2025 | Common Stock | SSaleDisposed | −6,760 | $75.29 | −$508,960.4 | 37,546 | Direct | |
| Sep 10, 2025 | Common Stock | SSaleDisposed | −13,240 | $75.93 | −$1,005,313.2 | 24,306 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Common Stock | MOption exerciseDisposed | −11,271 | $0.00 | $0 | 0 | Direct | |
| Sep 10, 2025 | Common Stock | MOption exerciseDisposed | −1,135 | $0.00 | $0 | 812 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.